Laboratorios Richmond SACIF Stock | RICH.BA | ARLRIC300027 |

Date	Laboratorios Richmond SACIF Price
10/25/2024	1,300.00 undefined
10/10/2024	930.00 undefined

Date	Laboratorios Richmond SACIF Revenue	Laboratorios Richmond SACIF EBIT	Laboratorios Richmond SACIF Net Income
2023	39.03 B undefined	5.31 B undefined	-10.85 B undefined
2022	18.47 B undefined	2.97 B undefined	163.43 M undefined
2021	32.37 B undefined	4.49 B undefined	1.15 B undefined
2020	9.33 B undefined	2.33 B undefined	733.94 M undefined
2019	5.3 B undefined	1.06 B undefined	158.52 M undefined
2018	2.8 B undefined	172.83 M undefined	-331.67 M undefined
2017	1.59 B undefined	196.33 M undefined	48.71 M undefined
2016	855.98 M undefined	240.51 M undefined	94.8 M undefined
2015	446.41 M undefined	98.62 M undefined	5.83 M undefined
2014	347.23 M undefined	58.73 M undefined	6.47 M undefined
2013	259.7 M undefined	25.5 M undefined	100,000 undefined
2012	240.1 M undefined	29.6 M undefined	4.1 M undefined

	Revenue	EBIT	Net Income
2012	240.1 M ARS	29.6 M ARS	4.1 M ARS
2013	259.7 M ARS	25.5 M ARS	100,000 ARS
2014	347.23 M ARS	58.73 M ARS	6.47 M ARS
2015	446.41 M ARS	98.62 M ARS	5.83 M ARS
2016	855.98 M ARS	240.51 M ARS	94.8 M ARS
2017	1.59 B ARS	196.33 M ARS	48.71 M ARS
2018	2.8 B ARS	172.83 M ARS	-331.67 M ARS
2019	5.3 B ARS	1.06 B ARS	158.52 M ARS
2020	9.33 B ARS	2.33 B ARS	733.94 M ARS
2021	32.37 B ARS	4.49 B ARS	1.15 B ARS
2022	18.47 B ARS	2.97 B ARS	163.43 M ARS
2023	39.03 B ARS	5.31 B ARS	-10.85 B ARS

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0.24	0.26	0.35	0.45	0.86	1.59	2.8	5.3	9.33	32.37	18.47	39.03
-	7.92	33.98	28.53	91.70	86.08	75.68	89.70	75.97	246.90	-42.93	111.30
43.33	47.88	48.99	55.38	55.32	49.28	44.29	48.55	48.72	29.66	47.26	52.66
0.1	0.12	0.17	0.25	0.47	0.78	1.24	2.57	4.55	9.6	8.73	20.55
0.03	0.03	0.06	0.1	0.24	0.2	0.17	1.06	2.33	4.49	2.97	5.31
12.08	9.65	16.71	21.97	28.07	12.32	6.15	20.03	24.95	13.88	16.08	13.61
0	0	0.01	0.01	0.09	0.05	-0.33	0.16	0.73	1.15	0.16	-10.85
-	-	-	-16.67	1,780.00	-48.94	-789.58	-147.73	363.92	57.16	-85.85	-6,756.44
66.6	66.6	66.58	66.58	66.58	80.75	80.75	80.75	80.75	80.75	80.75	80.75
-	-	-	-	-	-	-	-	-	-	-	-

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0.01	0	0.01	0.02	0.02	0.8	0.77	0.3	0.8	14.34	2.69	0.82
0.09	0.1	0.18	0.26	0.49	0.66	1.05	2.54	4.31	6.88	4.76	11.28
0.01	0.01	0.01	0.01	0.02	0.1	0.16	0.13	0.19	0.93	1.04	2.59
0.06	0.08	0.09	0.14	0.19	0.48	0.82	1.27	2.86	7.91	5.55	16.71
0	0	0	0	0	0	230.87	242.98	0	0	0	0
0.16	0.2	0.29	0.43	0.73	2.03	3.03	4.48	8.16	30.07	14.04	31.4
0.05	0.05	0.05	0.06	0.06	0.27	0.59	1.63	3.04	15.54	21.79	101
0	0	0	0	0.02	0.07	0.02	0.01	0.03	0.28	0.23	1.17
0.1	0.1	0.1	0.1	0.15	1.36	2.86	4.03	6.29	9.91	109.3	553.66
0.01	0.01	0.01	0.01	0.02	0.06	0.22	0.46	0.99	2.85	3.34	12.75
0.04	0.03	0.03	0.03	0.03	0.14	0.22	0.33	0.55	1.03	1.02	2.75
0	0	0	0.01	0	0	0.08	0.08	0.16	0.27	0.2	5.28
0.1	0.09	0.09	0.1	0.13	0.54	1.14	2.51	4.78	19.98	26.68	123.51
0.26	0.29	0.39	0.53	0.86	2.58	4.16	6.99	12.94	50.05	40.72	154.9

0.07	0.07	0.07	0.07	0.07	0.37	0.57	0.77	1.17	2.28	2.28	7.08
0	0	0	0	0	0.73	1.12	1.52	2.29	4.47	4.47	13.92
0.03	0.02	0.03	0.03	0.12	0.16	-0.11	0.45	1.56	3.78	3.78	1.49
0	0	0	0	0	0.09	42.21	47.2	78.2	-209.02	-431.72	57.72
0	0	0	0	0	0	0	0	0	0	0	0
0.09	0.09	0.09	0.1	0.19	1.25	1.62	2.79	5.1	10.31	10.09	22.55
0.06	0.06	0.1	0.16	0.23	0.55	1.32	2.53	3.56	11.15	4.79	23.76
0	0	0.01	0.01	0.01	0.04	0.05	0.06	0.15	0.35	0.48	1.75
0.01	0.01	0.01	0.03	0.1	0.09	0.06	0.25	0.52	3.11	0.86	1.13
0	0	0	0	0	0	0	0.44	299.73	0	0	0
0.04	0.09	0.12	0.14	0.21	0.4	0.5	0.51	0.83	3.56	2.91	9.67
0.12	0.15	0.24	0.34	0.55	1.09	1.92	3.36	5.36	18.17	9.03	36.31
0.02	0.02	0.01	0.03	0.02	0.04	0.15	0.26	1.48	18.81	18.54	84.49
0	0	0	0	0	0.06	0.23	0.36	0.65	2.57	2.9	11.08
23.9	24.9	39.6	66.4	101.3	132.5	151.86	147.96	246.35	23.96	27.64	80.55
0.05	0.04	0.05	0.1	0.12	0.23	0.53	0.78	2.38	21.41	21.47	95.65
0.17	0.2	0.29	0.44	0.67	1.32	2.45	4.13	7.73	39.58	30.5	131.95
0.26	0.29	0.39	0.53	0.86	2.58	4.07	6.92	12.84	49.89	40.59	154.5

Laboratorios Richmond SACIF Gross margin	Laboratorios Richmond SACIF Profit margin	Laboratorios Richmond SACIF EBIT margin	Laboratorios Richmond SACIF Profit margin
2023	52.66 %	13.61 %	-27.8 %
2022	47.26 %	16.09 %	0.88 %
2021	29.67 %	13.88 %	3.56 %
2020	48.73 %	24.96 %	7.87 %
2019	48.55 %	20.04 %	2.99 %
2018	44.3 %	6.18 %	-11.87 %
2017	49.29 %	12.34 %	3.06 %
2016	55.33 %	28.1 %	11.07 %
2015	55.42 %	22.09 %	1.31 %
2014	49.05 %	16.91 %	1.86 %
2013	47.75 %	9.82 %	0.04 %
2012	43.61 %	12.33 %	1.71 %

	Gross margin	EBIT margin	Profit margin
2012	43.61 %	12.33 %	1.71 %
2013	47.75 %	9.82 %	0.04 %
2014	49.05 %	16.91 %	1.86 %
2015	55.42 %	22.09 %	1.31 %
2016	55.33 %	28.1 %	11.07 %
2017	49.29 %	12.34 %	3.06 %
2018	44.3 %	6.18 %	-11.87 %
2019	48.55 %	20.04 %	2.99 %
2020	48.73 %	24.96 %	7.87 %
2021	29.67 %	13.88 %	3.56 %
2022	47.26 %	16.09 %	0.88 %
2023	52.66 %	13.61 %	-27.8 %

Date	Laboratorios Richmond SACIF Sales per Share	Laboratorios Richmond SACIF EBIT per share	Laboratorios Richmond SACIF Earnings per Share
2023	483.31 undefined	65.76 undefined	-134.37 undefined
2022	228.73 undefined	36.79 undefined	2.02 undefined
2021	400.81 undefined	55.62 undefined	14.27 undefined
2020	115.54 undefined	28.84 undefined	9.09 undefined
2019	65.67 undefined	13.16 undefined	1.96 undefined
2018	34.61 undefined	2.14 undefined	-4.11 undefined
2017	19.71 undefined	2.43 undefined	0.6 undefined
2016	12.86 undefined	3.61 undefined	1.42 undefined
2015	6.7 undefined	1.48 undefined	0.09 undefined
2014	5.21 undefined	0.88 undefined	0.1 undefined
2013	3.9 undefined	0.38 undefined	0 undefined
2012	3.61 undefined	0.44 undefined	0.06 undefined

	Sales per Share	EBIT per share	Earnings per Share
2012	3.61 ARS	0.44 ARS	0.06 ARS
2013	3.9 ARS	0.38 ARS	0 ARS
2014	5.21 ARS	0.88 ARS	0.1 ARS
2015	6.7 ARS	1.48 ARS	0.09 ARS
2016	12.86 ARS	3.61 ARS	1.42 ARS
2017	19.71 ARS	2.43 ARS	0.6 ARS
2018	34.61 ARS	2.14 ARS	-4.11 ARS
2019	65.67 ARS	13.16 ARS	1.96 ARS
2020	115.54 ARS	28.84 ARS	9.09 ARS
2021	400.81 ARS	55.62 ARS	14.27 ARS
2022	228.73 ARS	36.79 ARS	2.02 ARS
2023	483.31 ARS	65.76 ARS	-134.37 ARS

	Number of stocks
2012	66.6 M Aktien
2013	66.6 M Aktien
2014	66.58 M Aktien
2015	66.58 M Aktien
2016	66.58 M Aktien
2017	80.75 M Aktien
2018	80.75 M Aktien
2019	80.75 M Aktien
2020	80.75 M Aktien
2021	80.75 M Aktien
2022	80.75 M Aktien
2023	80.75 M Aktien

%	Name	Stocks	Change	Date
0.24315 %	Galicia Administradora de Fondos S.A. Sociedad Gerente	34,448	-652	9/30/2024
0.23631 %	Axis SGFCI SA	33,478	3,800	8/31/2024
0.10939 %	Zofingen Investment SA.	15,498	-1,163	3/31/2024
0 %	Invertir en Bolsa S.A	0	-3,475	10/31/2023

What values and corporate philosophy does Laboratorios Richmond SACIF represent?

Laboratorios Richmond SACIF represents values of integrity, innovation, and commitment to healthcare. With a strong corporate philosophy focused on research and development, the company endeavors to provide high-quality pharmaceutical products to patients worldwide. Laboratorios Richmond SACIF prioritizes ethical practices, ensuring that their operations comply with regulatory standards. Through collaboration with healthcare professionals and continuous improvement of their processes, Laboratorios Richmond SACIF aims to deliver effective and safe solutions to improve patient lives. With their dedication to excellence and customer satisfaction, Laboratorios Richmond SACIF has established itself as a trusted name in the pharmaceutical industry.

In which countries and regions is Laboratorios Richmond SACIF primarily present?

Laboratorios Richmond SACIF is primarily present in Argentina and Latin America.

What significant milestones has the company Laboratorios Richmond SACIF achieved?

Laboratorios Richmond SACIF has achieved significant milestones in its journey. The company has made remarkable progress in the pharmaceutical industry, establishing itself as a leading player. It has successfully developed and introduced a wide range of high-quality and innovative products, catering to various healthcare needs. Laboratorios Richmond SACIF has consistently expanded its global presence, forging strategic partnerships and collaborations worldwide. With a strong focus on research and development, the company has achieved numerous regulatory approvals, ensuring its products meet international standards. Laboratorios Richmond SACIF's commitment to excellence, market growth, and commitment to improving global health has contributed to its exceptional success and position as a trusted and prominent name in the pharmaceutical sector.

What is the history and background of the company Laboratorios Richmond SACIF?

Laboratorios Richmond SACIF is a leading pharmaceutical company with a rich history and strong background. Established in Argentina in 1948, Laboratorios Richmond has been dedicated to the research, development, and production of innovative and high-quality healthcare products. Over the years, the company has experienced significant growth and has become a trusted name in the pharmaceutical industry. Laboratorios Richmond SACIF has an extensive portfolio of branded and generic medications, catering to various therapeutic areas. With its commitment to excellence, cutting-edge technology, and a skilled team, the company continues to expand its presence globally, delivering reliable and affordable healthcare solutions to millions of people worldwide.

Who are the main competitors of Laboratorios Richmond SACIF in the market?

The main competitors of Laboratorios Richmond SACIF in the market include other pharmaceutical companies such as Roemmers, Bagó Group, and Laboratorios Andrómaco. These companies compete with Laboratorios Richmond SACIF in the manufacturing and distribution of pharmaceutical products, including prescription drugs and over-the-counter medications.

In which industries is Laboratorios Richmond SACIF primarily active?

Laboratorios Richmond SACIF is primarily active in the pharmaceutical industry.

What is the business model of Laboratorios Richmond SACIF?

The business model of Laboratorios Richmond SACIF involves the research, development, manufacturing, and commercialization of pharmaceutical products. As a leading Argentina-based pharmaceutical company, Laboratorios Richmond SACIF focuses on producing high-quality generics, biosimilars, and branded pharmaceuticals. With a strong commitment to innovation and compliance with international quality standards, the company aims to provide accessible and affordable healthcare solutions to patients worldwide. By leveraging its extensive experience and cutting-edge technology, Laboratorios Richmond SACIF strives to meet the diverse needs of consumers, healthcare professionals, and stakeholders in the pharmaceutical industry.

What is the P/E ratio of Laboratorios Richmond SACIF 2024?

The P/E ratio cannot be calculated for Laboratorios Richmond SACIF at the moment.

What is the P/S ratio of Laboratorios Richmond SACIF 2024?

The P/S cannot be calculated for Laboratorios Richmond SACIF currently.

What is the Quality Investing of Laboratorios Richmond SACIF?

The Quality Investing for Laboratorios Richmond SACIF is 5/10.

What is the revenue of Laboratorios Richmond SACIF 2024?

The revenue cannot currently be calculated for Laboratorios Richmond SACIF.

How high is the profit of Laboratorios Richmond SACIF 2024?

The profit cannot currently be calculated for Laboratorios Richmond SACIF.

What is the business model of Laboratorios Richmond SACIF

Laboratorios Richmond SACIF is an Argentine pharmaceutical company that was founded in 1950. It is a leading manufacturer and marketer of generics in Argentina and one of the most important manufacturers in the Latin American market. Laboratorios Richmond SACIF operates three production sites in Argentina and employs over 350 employees. Generics are medicines that contain the same active ingredient as brand-name drugs, but are sold at a lower price. Laboratorios Richmond SACIF produces a wide range of generics that are used in various therapeutic areas such as cardiology, gastroenterology, pain treatment, oncology, and others. The company operates in four main areas: generics, biosimilars, medical devices, and veterinary drugs. In the generics sector, Laboratorios Richmond SACIF offers a variety of products including pills, capsules, injections, eye drops, and ointments. The company produces generics for well-known brand-name drugs such as Viagra, Lipitor, and Zovirax, to name a few. In the biosimilars sector, Laboratorios Richmond SACIF produces drugs that contain biological molecules and are used to treat diseases such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are copies of biopharmaceuticals that are manufactured in cells. Laboratorios Richmond SACIF has built an extensive portfolio of biosimilars, including Enbrel, MabThera, and Humira. In the medical devices sector, Laboratorios Richmond SACIF offers a wide range of products used in medicine, including surgical disposable products, orthopedic implants, and cardiology devices. In the veterinary drugs sector, the company produces drugs for livestock and pets. Laboratorios Richmond SACIF offers a wide range of veterinary drugs, including antibiotics, vaccines, and anthelmintics. Laboratorios Richmond SACIF has expanded its presence in Latin America and worldwide, exporting its products to over 50 countries. The company has also established partnerships with international pharmaceutical companies such as Pfizer and Takeda to increase its reach and capacity. The business model of Laboratorios Richmond SACIF is based on providing high-quality and affordable medicines that cover a wide range of diseases and needs. The company has a clear strategy to expand its position in the Latin American market and diversify its product lines to respond to changing market demands. Overall, Laboratorios Richmond SACIF is an innovative and strong pharmaceutical company specialized in high-quality generics, biosimilars, medical devices, and veterinary drugs. With its various business sectors, the company is well-positioned to continue growing and increase its market share in the future.

What is the Laboratorios Richmond SACIF dividend?

Laboratorios Richmond SACIF pays a dividend of 0 ARS distributed over payouts per year.

How often does Laboratorios Richmond SACIF pay dividends?

The dividend cannot currently be calculated for Laboratorios Richmond SACIF or the company does not pay out a dividend.

What is the Laboratorios Richmond SACIF ISIN?

The ISIN of Laboratorios Richmond SACIF is ARLRIC300027.

What is the Laboratorios Richmond SACIF ticker?

The ticker of Laboratorios Richmond SACIF is RICH.BA.

How much dividend does Laboratorios Richmond SACIF pay?

Over the past 12 months, Laboratorios Richmond SACIF paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Laboratorios Richmond SACIF is expected to pay a dividend of 0 ARS.

What is the dividend yield of Laboratorios Richmond SACIF?

The current dividend yield of Laboratorios Richmond SACIF is .

When does Laboratorios Richmond SACIF pay dividends?

Laboratorios Richmond SACIF pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Laboratorios Richmond SACIF?

Laboratorios Richmond SACIF paid dividends every year for the past 0 years.

What is the dividend of Laboratorios Richmond SACIF?

For the upcoming 12 months, dividends amounting to 0 ARS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Laboratorios Richmond SACIF located?

Laboratorios Richmond SACIF is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Richmond SACIF kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Richmond SACIF from 11/1/2024 amounting to 0 ARS, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Laboratorios Richmond SACIF pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Laboratorios Richmond SACIF in the year 2023?

In the year 2023, Laboratorios Richmond SACIF distributed 0 ARS as dividends.

In which currency does Laboratorios Richmond SACIF pay out the dividend?

The dividends of Laboratorios Richmond SACIF are distributed in ARS.

Scope 1 - Direct Emissions	—
Scope 2 - Indirect emissions from purchased energy	—
Scope 3 - Indirect emissions within the value chain	—
Total CO₂ emissions	1,360
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	❌
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	✅
Environmentally friendly packaging	✅
Hazardous substances	✅
Fuel consumption and efficiency	❌
Water consumption and efficiency	✅

Percentage of female employees	42
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	❌
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Environmental reporting	✅
Stakeholder Engagement	✅
Call Back Policies	❌
Antitrust law	❌

Stock Exchange	Laboratorios Richmond SACIF Ticker
BME	ROVI.MC
EURONEXT	ROVI.MC

Laboratorios Richmond SACIF Ticker	Laboratorios Richmond SACIF FIGI
RICH:AR	BBG002PWNQ31
RICH:AF	BBG00JHPRXB0

Access the world's leading financial data and tools

Price

Price

TickerRICH.BA

ISINARLRIC300027

Laboratorios Richmond SACIF stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Laboratorios Richmond SACIF Stock Price History

Laboratorios Richmond SACIF Revenue, EBIT, Net Income ARLRIC300027 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Laboratorios Richmond SACIF Revenue, EBIT and net profit per share

Laboratorios Richmond SACIF Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Laboratorios Richmond SACIF stock margins ARLRIC300027 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Laboratorios Richmond SACIF Margin History

Laboratorios Richmond SACIF Stock Sales Revenue, EBIT, Earnings per Share ARLRIC300027 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Laboratorios Richmond SACIF Revenue, EBIT and net profit per share

Laboratorios Richmond SACIF business model

Laboratorios Richmond SACIF SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Laboratorios Richmond SACIF Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Laboratorios Richmond SACIF historical P/E ratio, EBIT multiple, and P/S ratio

Laboratorios Richmond SACIF shares outstanding ARLRIC300027 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Laboratorios Richmond SACIF Earnings Estimates

Laboratorios Richmond SACIF latest earnings and earnings surprises

Eulerpool ESG Scorecard© for the Laboratorios Richmond SACIF stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Ticker
RICH.BA

ISIN
ARLRIC300027